title: Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile.
abstract: Patients at high risk for hypertension may require several therapeutic agents to lower their blood pressure to guideline-recommended targets. Some antihypertensive agents are more effective than others in protecting against cardiovascular morbidity and mortality. Numerous beta-blocking agents have been approved by the US Food and Drug Administration (FDA) for the treatment of hypertension. Previous trials have demonstrated that although all beta-blockers effectively reduce blood pressure, there are differences in how they affect various metabolic factors. In 2 trials, a novel controlled-release (CR) formulation of carvedilol will be tested against other selective beta-blockers to determine whether differences exist in their individual effects on cardiovascular risk factors. These will be the first head-to-head trials using carvedilol CR to determine whether the differing pharmacologic actions among beta-blockers result in varying effects on cardiovascular risk factors.
authors.affiliation: Hypertension Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA. gbakris@earthlink.net
authors.forename: George L
authors.initials: GL
authors.lastname: Bakris
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Tarka
authors.forename: Brian
authors.initials: B
authors.lastname: Waterhouse
authors.forename: Michelle R
authors.initials: MR
authors.lastname: Goulding
authors.forename: Anuradha
authors.initials: A
authors.lastname: Madan
authors.forename: Karen M
authors.initials: KM
authors.lastname: Anderson
authors.forename: Martin
authors.initials: M
authors.lastname: St John Sutton
authors.forename: Alan B
authors.initials: AB
authors.lastname: Miller
authors.forename: Nathaniel
authors.initials: N
authors.lastname: Reichek
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002227:Carbazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000077261:Carvedilol; D003692:Delayed-Action Preparations / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D017379:Hypertrophy, Left Ventricular / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012307:Risk Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002227:Carbazoles; D003692:Delayed-Action Preparations; D000960:Hypolipidemic Agents; D011412:Propanolamines; D000077261:Carvedilol